SK79999A3 - Use of comt inhibitors for the manufacture of a medicament for the prevention of diabetic vascular dysfunctions - Google Patents

Use of comt inhibitors for the manufacture of a medicament for the prevention of diabetic vascular dysfunctions Download PDF

Info

Publication number: SK79999A3
Authority: SK; Slovakia
Prior art keywords: prevention; medicament; manufacture; nitecapone; rats
Prior art date: 1996-12-20

Application number

SK799-99A

Other languages

English (en)

Slovak (sk)

Inventor

Inge-Britt Yvonne Linden

Anita Chatarina Aperia

Original Assignee

Orion Yhtymae Oy

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-12-20

Filing date

1997-12-19

Publication date

2000-05-16

1997-12-19 Application filed by Orion Yhtymae Oy filed Critical Orion Yhtymae Oy

2000-05-16 Publication of SK79999A3 publication Critical patent/SK79999A3/sk

Links

206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 26
239000003543 catechol methyltransferase inhibitor Substances 0.000 title claims abstract description 14
230000006492 vascular dysfunction Effects 0.000 title claims abstract description 8
239000003814 drug Substances 0.000 title claims description 11
230000002265 prevention Effects 0.000 title claims description 11
238000004519 manufacturing process Methods 0.000 title claims description 10
UPMRZALMHVUCIN-UHFFFAOYSA-N Nitecapone Chemical compound CC(=O)C(C(C)=O)=CC1=CC(O)=C(O)C([N+]([O-])=O)=C1 UPMRZALMHVUCIN-UHFFFAOYSA-N 0.000 claims description 29
150000003839 salts Chemical class 0.000 claims description 9
150000002148 esters Chemical class 0.000 claims description 7
208000017442 Retinal disease Diseases 0.000 claims description 5
206010038923 Retinopathy Diseases 0.000 claims description 5
208000017169 kidney disease Diseases 0.000 claims description 4
201000001119 neuropathy Diseases 0.000 claims description 4
230000007823 neuropathy Effects 0.000 claims description 4
208000033808 peripheral neuropathy Diseases 0.000 claims description 4
206010062198 microangiopathy Diseases 0.000 claims 1
229950008980 nitecapone Drugs 0.000 description 25
241000700159 Rattus Species 0.000 description 23
230000000694 effects Effects 0.000 description 11
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 6
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
239000008103 glucose Substances 0.000 description 5
229960001052 streptozocin Drugs 0.000 description 5
238000012360 testing method Methods 0.000 description 4
102000009027 Albumins Human genes 0.000 description 3
108010088751 Albumins Proteins 0.000 description 3
208000007342 Diabetic Nephropathies Diseases 0.000 description 3
102000003923 Protein Kinase C Human genes 0.000 description 3
108090000315 Protein Kinase C Proteins 0.000 description 3
208000001647 Renal Insufficiency Diseases 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
208000033679 diabetic kidney disease Diseases 0.000 description 3
230000029142 excretion Effects 0.000 description 3
201000006370 kidney failure Diseases 0.000 description 3
238000000034 method Methods 0.000 description 3
102000006378 Catechol O-methyltransferase Human genes 0.000 description 2
108020002739 Catechol O-methyltransferase Proteins 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000003651 drinking water Substances 0.000 description 2
235000020188 drinking water Nutrition 0.000 description 2
239000003349 gelling agent Substances 0.000 description 2
230000001434 glomerular Effects 0.000 description 2
230000024924 glomerular filtration Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
230000003907 kidney function Effects 0.000 description 2
239000000203 mixture Substances 0.000 description 2
-1 oxalic Chemical class 0.000 description 2
239000002904 solvent Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
239000005541 ACE inhibitor Substances 0.000 description 1
206010001580 Albuminuria Diseases 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
244000248349 Citrus limon Species 0.000 description 1
235000005979 Citrus limon Nutrition 0.000 description 1
208000002249 Diabetes Complications Diseases 0.000 description 1
206010012655 Diabetic complications Diseases 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
206010058061 Gastrointestinal oedema Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
239000000654 additive Substances 0.000 description 1
238000002266 amputation Methods 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000002775 capsule Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000003086 colorant Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000004744 fabric Substances 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000008187 granular material Substances 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
230000004089 microcirculation Effects 0.000 description 1
230000001452 natriuretic effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
210000003462 vein Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

SK799-99A 1996-12-20 1997-12-19 Use of comt inhibitors for the manufacture of a medicament for the prevention of diabetic vascular dysfunctions SK79999A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9626472.6A GB9626472D0 (en)	1996-12-20	1996-12-20	New use of comt inhibitors
PCT/FI1997/000812 WO1998027973A1 (en)	1996-12-20	1997-12-19	Use of comt inhibitors for the manufacture of a medicament for the prevention of diabetic vascular dysfunctions

Publications (1)

Publication Number	Publication Date
SK79999A3 true SK79999A3 (en)	2000-05-16

Family

ID=10804746

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK799-99A SK79999A3 (en)	1996-12-20	1997-12-19	Use of comt inhibitors for the manufacture of a medicament for the prevention of diabetic vascular dysfunctions

Country Status (23)

Country	Link
US (1)	US6207706B1 (de)
EP (1)	EP0964678B1 (de)
JP (1)	JP2001507006A (de)
KR (1)	KR20000057628A (de)
AT (1)	ATE234613T1 (de)
AU (1)	AU714086B2 (de)
BG (1)	BG103491A (de)
CA (1)	CA2275681A1 (de)
CZ (1)	CZ291117B6 (de)
DE (1)	DE69720064D1 (de)
EA (1)	EA001673B1 (de)
EE (1)	EE9700350A (de)
GB (1)	GB9626472D0 (de)
HU (1)	HUP0001097A3 (de)
IL (1)	IL130500A (de)
NO (1)	NO992985L (de)
NZ (1)	NZ336043A (de)
PL (1)	PL334093A1 (de)
SK (1)	SK79999A3 (de)
TR (1)	TR199901206T2 (de)
WO (1)	WO1998027973A1 (de)
YU (1)	YU28599A (de)
ZA (1)	ZA9711468B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI20000635A0 (fi)	2000-03-17	2000-03-17	Orion Yhtymae Oyj	COMT-inhibiittoreiden käyttö analgeettina
FI20001593A7 (fi)	2000-07-03	2002-01-04	Orion Yhtymo Oyj	Comt-entsyymiõ inhiboivaa aktiivisuutta omaavia kumariinijohdannaisia
FI20002044A0 (fi)	2000-09-15	2000-09-15	Orion Yhtymae Oyj	Comt-entsyymiä estäviä naftaleenijohdannaisia
MY148644A (en) *	2005-07-18	2013-05-15	Orion Corp	New pharmaceutical compounds
TWI638802B (zh)	2012-05-24	2018-10-21	芬蘭商奧利安公司	兒茶酚ｏ－甲基轉移酶活性抑制化合物
US20210347728A1 (en)	2018-07-25	2021-11-11	Orion Corporation	4,5-dihydroxy-2-(4-methylbenzyl)isophthalonitrile solvates and crystalline forms thereof
JP2022506697A (ja)	2018-11-09	2022-01-17	オリオンコーポレーション	４，５－ジヒドロキシ－２－（４－メチルベンジル）イソフタロニトリルの製造方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4672042A (en)	1981-12-21	1987-06-09	Orion Research Puerto Rico, Inc.	Method of and apparatus for chromatographic analysis
DK175069B1 (da)	1986-03-11	2004-05-24	Hoffmann La Roche	Pyrocatecholderivater
US5236952A (en) *	1986-03-11	1993-08-17	Hoffmann-La Roche Inc.	Catechol derivatives
FI864875A0 (fi)	1986-11-28	1986-11-28	Orion Yhtymae Oy	Nya farmakologiskt aktiva foereningar, dessa innehaollande kompositioner samt foerfarande och mellanprodukter foer anvaendning vid framstaellning av dessa.
US5283352A (en)	1986-11-28	1994-02-01	Orion-Yhtyma Oy	Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
YU213587A (en)	1986-11-28	1989-06-30	Orion Yhtymae Oy	Process for obtaining new pharmacologic active cateholic derivatives
US5489614A (en)	1987-11-27	1996-02-06	Orion-Yhtyma Oy	Catechol derivatives, their physiologically acceptable salts, esters and use
MTP1031B (en) *	1987-12-24	1990-10-04	Orion Yhtymae Oy	New use of cathecol-o-methyl transferase (comt) inhibitors and their physiologically acceptable salts and esters
US5185370A (en)	1988-09-01	1993-02-09	Orion-Yhtyma Oy	Substituted β-diketones and their use
IL91382A (en)	1988-09-01	1995-06-29	Orion Yhtymae Oy	Alkenyl or arylmethylene-substituted beta-diketones their preparation and pharmaceutical compositions containing them
GB8903130D0 (en)	1989-02-11	1989-03-30	Orion Yhtymae Oy	Substituted pyridazinones
US5185332A (en)	1989-02-11	1993-02-09	Orion-Yhtyma Oy	Thiadiazines and pharmaceutical compositions thereof as well as method of use
GB9510481D0 (en)	1995-05-24	1995-07-19	Orion Yhtymae Oy	New catechol derivatives

1996
- 1996-12-20 GB GBGB9626472.6A patent/GB9626472D0/en active Pending
1997
- 1997-12-19 EA EA199900579A patent/EA001673B1/ru not_active IP Right Cessation
- 1997-12-19 CA CA002275681A patent/CA2275681A1/en not_active Abandoned
- 1997-12-19 YU YU28599A patent/YU28599A/sh unknown
- 1997-12-19 ZA ZA9711468A patent/ZA9711468B/xx unknown
- 1997-12-19 TR TR1999/01206T patent/TR199901206T2/xx unknown
- 1997-12-19 EE EE9700350A patent/EE9700350A/xx unknown
- 1997-12-19 JP JP52844098A patent/JP2001507006A/ja active Pending
- 1997-12-19 US US09/331,113 patent/US6207706B1/en not_active Expired - Fee Related
- 1997-12-19 KR KR1019990705423A patent/KR20000057628A/ko not_active Ceased
- 1997-12-19 AT AT97948919T patent/ATE234613T1/de not_active IP Right Cessation
- 1997-12-19 WO PCT/FI1997/000812 patent/WO1998027973A1/en not_active Ceased
- 1997-12-19 HU HU0001097A patent/HUP0001097A3/hu unknown
- 1997-12-19 IL IL13050097A patent/IL130500A/xx not_active IP Right Cessation
- 1997-12-19 DE DE69720064T patent/DE69720064D1/de not_active Expired - Lifetime
- 1997-12-19 PL PL97334093A patent/PL334093A1/xx unknown
- 1997-12-19 NZ NZ336043A patent/NZ336043A/xx unknown
- 1997-12-19 EP EP97948919A patent/EP0964678B1/de not_active Expired - Lifetime
- 1997-12-19 CZ CZ19992231A patent/CZ291117B6/cs not_active IP Right Cessation
- 1997-12-19 SK SK799-99A patent/SK79999A3/sk unknown
- 1997-12-19 AU AU78711/98A patent/AU714086B2/en not_active Ceased
1999
- 1999-06-14 BG BG103491A patent/BG103491A/bg unknown
- 1999-06-17 NO NO992985A patent/NO992985L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
TR199901206T2 (xx)	1999-08-23
EA199900579A1 (ru)	1999-12-29
AU714086B2 (en)	1999-12-16
ATE234613T1 (de)	2003-04-15
AU7871198A (en)	1998-07-17
IL130500A0 (en)	2000-06-01
NO992985D0 (no)	1999-06-17
CA2275681A1 (en)	1998-07-02
CZ223199A3 (cs)	1999-11-17
EE9700350A (et)	1998-10-15
US6207706B1 (en)	2001-03-27
JP2001507006A (ja)	2001-05-29
ZA9711468B (en)	1998-08-29
KR20000057628A (ko)	2000-09-25
PL334093A1 (en)	2000-01-31
YU28599A (sh)	2002-03-18
EP0964678A1 (de)	1999-12-22
DE69720064D1 (de)	2003-04-24
HUP0001097A3 (en)	2003-05-28
WO1998027973A1 (en)	1998-07-02
NO992985L (no)	1999-06-17
HUP0001097A2 (hu)	2000-09-28
NZ336043A (en)	2000-12-22
CZ291117B6 (cs)	2002-12-11
IL130500A (en)	2003-02-12
GB9626472D0 (en)	1997-02-05
BG103491A (bg)	2000-04-28
EA001673B1 (ru)	2001-06-25
EP0964678B1 (de)	2003-03-19

Publication	Publication Date	Title
DE69623634T2 (de)	2003-05-22	Pharmazeutische zusammensetzung von l-dopa ethyl ester
DE69113938T2 (de)	1996-04-11	Zusammensetzungen von Maillard-Reaktion inhibitoren.
DE3872029T2 (de)	1992-12-03	Rektal absorbierbare form von l-dopa.
DE19823831A1 (de)	1999-12-02	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE2759543C2 (de)	1987-04-09	Verwendung von Spiro-hydantoin-Verbindungen bei der Bekämpfung von Diabetes
EP0240484B1 (de)	1992-01-15	Pharmazeutische Zubereitung sowie Verfahren zur Herstellung derselben
EP0150063B1 (de)	1990-07-11	Therapeutische und vorbeugende ophthalmische Lösung für intraokuläre Hypertension und Glaukoma
DE69232942T2 (de)	2003-12-24	Produkte zur behandlung von glaukoma
EP0964678B1 (de)	2003-03-19	Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen
EP0224810B1 (de)	1989-07-19	Antihypertensives Kombinationspräparat
AT400519B (de)	1996-01-25	Pharmazeutische zubereitungen mit einem gehalt an ace-inhibitor und dessen stabilisierung
EP0895782B1 (de)	2004-12-01	"Gegen Racemisierung stabilisierte pharmazeutische Zubereitungen von Cilansetron"
EP0649654B1 (de)	1999-02-10	Verwendung einer Kombination aus Angiotensin-Converting-Enzyme-Hemmer und Calciumantagonist zur Behandlung einer Proteinurie
EP1178787B1 (de)	2003-07-30	Pharmazeutische zusammensetzungen, bestimmt zur oralen verabreichung von phloroglucinol sowie deren herstellung
EP0278449B1 (de)	1992-09-30	Wirkstoff mit die Nierenfunktion verbesserndem und diuretischem Effekt und Verwendung eines darin enthaltenen Benzothiazepin-Derivates
MXPA99005706A (en)	2000-05-01	Use of comt inhibitors for the manufacture of a medicament for the prevention of diabetic vascular dysfunctions
DD141995A5 (de)	1980-06-04	Verfahren zur herstellung detoxifizierter zubereitungen von cytostatika
KR101016595B1 (ko)	2011-02-22	수성액제 및 광안정화된 수성액제
DE4001496C2 (de)	2001-05-10	Niedrig dosierte Zusammensetzung enthaltend Benazepril und Hydrochlorthiazid
EP0489043B1 (de)	1994-02-02	Verwendung des (+)-enantiomeren von anipamil
JPH0119A (ja)	1989-01-05	腎機能改善剤
DE3714322C2 (de)	1996-02-22	Prophylaktisches und therapeutisches Mittel für hepatische Krankheiten
DE69427927T2 (de)	2002-04-11	Verwendung von Trimetazidin zur Herstellung von Medikamenten für die Behandlung von Gesundheitsstörungen, die durch die Nephrotoxizität von Cyclosporin A bedingt sind.
CN1240351A (zh)	2000-01-05	Comt抑制剂在制备用于预防糖尿病性血管功能失调药物方面的用途
DE4109134A1 (de)	1992-09-24	Erzeugnisse, enthaltend verapamil und trandolapril